Compare Centrus Energy Corp (LEU) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Organon & Co. Common Stock — how do they compare? Centrus Energy Corp trades at $117.3 (market cap $2.75B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 31 Days and Organon & Co. Common Stock for 0 Days on average.
| LEU | OGN | |
|---|---|---|
Market Cap | $2.75B | $3.62B |
Volume | 573,041 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $436.00 | $13.81 |
52-Week Low | $119.95 | $5.70 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.06B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with $448.70M revenue and $77.80M net income for 2025, though profitability declined in 2026. Recent multi-year HALEU supply contracts with Antares and Radiant highlight Centrus' strategic position in the nuclear fuel market as the only US-licensed HALEU producer.
The stock presents a compelling growth opportunity in nuclear energy infrastructure with 46% analyst buy ratings and $218.10 consensus price target, but faces execution risks amid high valuation multiples (P/E 71.05) and recent earnings volatility. Key risks include dependency on nuclear policy support and competitive pressures in uranium enrichment.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
